France dilutes comparative trial demand, axes class actions as reform bill proceeds
This article was originally published in Scrip
Executive Summary
The bill on strengthening the French drug regulatory system has returned to the lower house for a second reading, with several changes including one that waters down the senate's proposal to require comparative trials against the gold-standard comparator for reimbursement purposes.